Statins-mediated inhibition of rho GTPases as a potential tool in anti-tumor therapy.
Rho GTPases, which control processes such as cell proliferation and cytoskeleton remodeling, are often hyper-expressed in tumors. Several members, such as RhoA/B/C, must be isoprenylated to interact with their effectors. Statins, by inhibiting the synthesis of prenyl groups, may affect RhoA/B/C activity and represent a promising tool in anticancer therapy.
Department of Genetics, Biology and Biochemistry, Research Center on Experimental Medicine (CeRMS), University of Torino, Torino, Italy.
Chiara
C
Riganti
Elisabetta
E
Aldieri
Sophie
S
Doublier
Amalia
A
Bosia
Dario
D
Ghigo
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D045744:Cell Line, Tumor; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology*; D008954:Models, Biological; D054876:Prenylation; D020741:rho GTP-Binding Proteins / Q000037:antagonists & inhibitors* / Q000378:metabolism
D000970:Antineoplastic Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D020741:rho GTP-Binding Proteins